Literature DB >> 31004023

Possibilities and limitations of an in vitro three-dimensional bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma.

Maaike V J Braham1, Jacqueline Alblas1, Wouter J A Dhert1,2, F Cumhur Öner1, Monique C Minnema3.   

Abstract

Entities:  

Year:  2019        PMID： 31004023      PMCID： PMC6821629          DOI： 10.3324/haematol.2018.213355

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Treatment of relapsed and refractory multiple myeloma.

Authors:  Pieter Sonneveld; Annemiek Broijl
Journal:  Haematologica       Date:  2016-08       Impact factor: 9.941

Review 2.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Authors:  Sarah A Holstein; Philip L McCarthy
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  Multiple myeloma.

Authors:  Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson
Journal:  Nat Rev Dis Primers       Date:  2017-07-20       Impact factor: 52.329

Review 4.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

5.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Authors:  Julia Kirshner; Kyle J Thulien; Lorri D Martin; Carina Debes Marun; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

6.  Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.

Authors:  Michaela R Reagan; Yuji Mishima; Siobhan V Glavey; Yong Zhang; Salomon Manier; Zhi Ning Lu; Masoumeh Memarzadeh; Yu Zhang; Antonio Sacco; Yosra Aljawai; Jiantao Shi; Yu-Tzu Tai; John E Ready; David L Kaplan; Aldo M Roccaro; Irene M Ghobrial
Journal:  Blood       Date:  2014-09-09       Impact factor: 22.113

7.  Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

Authors:  Muntasir Mamun Majumder; Raija Silvennoinen; Pekka Anttila; David Tamborero; Samuli Eldfors; Bhagwan Yadav; Riikka Karjalainen; Heikki Kuusanmäki; Juha Lievonen; Alun Parsons; Minna Suvela; Esa Jantunen; Kimmo Porkka; Caroline A Heckman
Journal:  Oncotarget       Date:  2017-05-05

8.  A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.

Authors:  Jana Jakubikova; Danka Cholujova; Teru Hideshima; Paulina Gronesova; Andrea Soltysova; Takeshi Harada; Jungnam Joo; Sun-Young Kong; Raphael E Szalat; Paul G Richardson; Nikhil C Munshi; David M Dorfman; Kenneth C Anderson
Journal:  Oncotarget       Date:  2016-11-22

9.  Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.

Authors:  Daniela Belloni; Silvia Heltai; Maurilio Ponzoni; Antonello Villa; Barbara Vergani; Lorenza Pecciarini; Magda Marcatti; Stefania Girlanda; Giovanni Tonon; Fabio Ciceri; Federico Caligaris-Cappio; Marina Ferrarini; Elisabetta Ferrero
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

10.  Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Authors:  Maaike V J Braham; Monique C Minnema; Tineke Aarts; Zsolt Sebestyen; Trudy Straetemans; Anna Vyborova; Jurgen Kuball; F Cumhur Öner; Catherine Robin; Jacqueline Alblas
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.